
    
      Treatment will consist of 28-days cycles with:

        -  Arm 1 (experimental arm):

             -  Carfilzomib administered iv at a dose of 70 mg/m2 (20 mg/m2 only in the first
                infusion) iv on days 1, 8 and 15.

             -  Dexamethasone at a dose of 20 mg po (10 mg for patients >75 years) days 1, 2, 8, 9,
                15 and 16.

             -  Cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15

        -  Arm 2 (control arm):

             -  Carfilzomib administered iv at a dose of 70 mg/m2 (20 mg/m2 only in the first
                infusion) iv on days 1, 8, and 15.

             -  Dexamethasone at a dose of 20 mg po (10 mg for patients >75 years) days 1, 2, 8, 9,
                15 and 16.

      Once the first 12 cycles are administered, treatment will be administered on days 1 and 15 of
      each cycle and the visit and doses on day 8 will be omitted in both study arms.

      Patients older than 75 years will receive in both arms carfilzomib at a dose of 56 mg/m2 (20
      mg/m2 only in the first infusion) during the cycles 1 and 2. If tolerability is acceptable,
      the dose could be increased up to 70 mg/m2 since the cycle 3.

      Treatments will be administered until progressive disease (PD) or unacceptable toxicity.
      Carfilzomib and cyclophosphamide will be provided by the sponsor. Dexamethasone may be
      utilized per a site's standard practice and will not be provided by the sponsor.
    
  